346 related articles for article (PubMed ID: 7083205)
21. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
22. Antiestrogen treatment of breast cancer: an overview.
Pearson OH; Manni A; Arafah BM
Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
[TBL] [Abstract][Full Text] [Related]
23. Significance of aromatase activity in human breast cancer.
Miller WR; Hawkins RA; Forrest AP
Cancer Res; 1982 Aug; 42(8 Suppl):3365s-3368s. PubMed ID: 7083201
[TBL] [Abstract][Full Text] [Related]
24. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
[TBL] [Abstract][Full Text] [Related]
25. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
[TBL] [Abstract][Full Text] [Related]
26. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.
Santen RJ; Worgul TJ; Lipton A; Harvey H; Boucher A; Samojlik E; Wells SA
Ann Intern Med; 1982 Jan; 96(1):94-101. PubMed ID: 7053713
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen and aminoglutethimide in advanced breast cancer.
Corkery J; Leonard RC; Henderson IC; Gelman RS; Hourihan J; Ascoli DM; Salhanick HA
Cancer Res; 1982 Aug; 42(8 Suppl):3409s-3414s. PubMed ID: 7044523
[TBL] [Abstract][Full Text] [Related]
28. [Hormonal therapy with aromatase inhibitor in advanced breast cancer].
Vrbanec D; Belev B; Pavlinić-Diminić V; Pezerović D; Dusper B; Plestina S; Unusić J
Lijec Vjesn; 1998; 120(10-11):315-8. PubMed ID: 19658346
[TBL] [Abstract][Full Text] [Related]
29. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
[TBL] [Abstract][Full Text] [Related]
30. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
[TBL] [Abstract][Full Text] [Related]
31. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
32. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
33. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
Bruning PF; Bonfrer JM; De Jong-Bakker M; Nooyen W
J Steroid Biochem; 1984 Sep; 21(3):293-8. PubMed ID: 6092781
[TBL] [Abstract][Full Text] [Related]
34. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
35. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
Trunet PF; Vreeland F; Royce C; Chaudri HA; Cooper J; Bhatnagar AS
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
[TBL] [Abstract][Full Text] [Related]
36. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
37. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
38. Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors.
Abul-Hajj YJ
Cancer Res; 1982 Aug; 42(8 Suppl):3373s-3377s. PubMed ID: 6211227
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
[TBL] [Abstract][Full Text] [Related]
40. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
